Edwards Lifesciences stock up 726% in 15 years, beating market

scanx
Reviewed by
Naman SScanX News Team
Key Highlights

Edwards Lifesciences shares have risen significantly over the last 15 years, turning a $100 investment into $826.43. The stock achieved a 15.06% annualized return, exceeding market performance by 1.31%, with the company now valued at $53.35 billion.

powered bylight_fuzz_icon
48203916

*this image is generated using AI for illustrative purposes only.

Edwards Lifesciences (NYSE: EW) has generated an average annual return of 15.06% over the past 15 years, outperforming the broader market by 1.31% on an annualized basis. The medical device manufacturer currently holds a market capitalization of $53.35 billion.

An investor who purchased $100 of EW stock 15 years ago would see that position grow to $826.43 today. This valuation is based on the company's share price of $92.56 at the time of writing.

Performance Metrics

The long-term performance data highlights the impact of compounded returns on capital growth over extended periods. The key figures from the 15-year period are detailed below:

Metric: Value
Average Annual Return: 15.06%
Market Outperformance: 1.31% (annualized)
Current Market Cap: $53.35 billion
Current Share Price: $92.56
15-Year Growth ($100): $826.43

What the Numbers Show

The divergence between the absolute growth of the investment ($826.43 from $100) and the modest annualized outperformance (1.31%) illustrates the baseline strength of the broader market over this period. While Edwards Lifesciences delivered strong absolute returns, the majority of the total return was driven by general market appreciation rather than alpha generation relative to the benchmark.

Can Edwards Lifesciences sustain its 15% annualized return given the maturing addressable market for transcatheter heart valves?

How might increasing regulatory scrutiny on medical device pricing impact EW's future profit margins and total shareholder return?

What role will emerging competitors in structural heart interventions play in eroding Edwards' current market share over the next decade?

like18
dislike

Truist raises Edwards Lifesciences target to $95

scanx
Reviewed by
Radhika SScanX News Team
Key Highlights

Truist Securities maintained a Hold rating on Edwards Lifesciences and raised the price target to $95 from $90, joining other firms like Mizuho, RBC Capital, BTIG, Evercore ISI Group, and Citigroup in revising targets.

powered bylight_fuzz_icon
44369316

*this image is generated using AI for illustrative purposes only.

Edwards Lifesciences (NYSE: EW) has received a raised price target from Truist Securities, adding to a series of analyst revisions. The adjustments reflect updated perspectives on the medical device company's valuation potential and market positioning.

Truist Securities analyst Richard Newitter maintained a Hold rating and increased the price target to $95 from $90. This aligns with adjustments from other firms. Mizuho analyst Anthony Petrone maintained an Outperform rating and increased the price target to $105 from $100. RBC Capital analyst Shagun Singh maintained an Outperform rating and increased the price target to $110 from $100. BTIG analyst Marie Thibault maintained a Buy rating and raised the price target to $110 from $100. Evercore ISI Group analyst Vijay Kumar kept an Outperform rating and lifted the price target to $100, up from $93. Citigroup analyst Joanne Wuensch maintained a Buy rating and raised the price target from $101 to $110.

Analyst Ratings and Price Targets

The revised targets from all six firms underscore varied optimism for the company's stock trajectory.

Firm Analyst Rating Previous Target New Target
Truist Securities Richard Newitter Hold $90 $95
Mizuho Anthony Petrone Outperform $100 $105
RBC Capital Shagun Singh Outperform $100 $110
BTIG Marie Thibault Buy $100 $110
Evercore ISI Group Vijay Kumar Outperform $93 $100
Citigroup Joanne Wuensch Buy $101 $110

Edwards Lifesciences continues to trade on the NYSE under the ticker EW.

What specific market trends or product developments are driving the consensus among analysts to raise price targets?

How might Edwards Lifesciences' recent performance influence future analyst ratings and investor sentiment?

What potential risks or challenges could offset the current optimism reflected in the revised price targets?

like15
dislike

More News on Edwards Lifesciences Corp